Related Experiment Videos
Antiplatelet agents for preventing pre-eclampsia and its complications
L Duley1, D J Henderson-Smart, M Knight
1Resource Centre for Randomised Trials, Institute of Health Sciences, Old Road, Headington, Oxford, UK, OX3 7LF.
The Cochrane Database of Systematic Reviews
|February 20, 2004
Summary
Antiplatelet agents, such as low-dose aspirin, can help prevent pre-eclampsia (pregnancy-induced hypertension) and reduce the risk of fetal death. Further research is needed to determine optimal usage for specific patient groups.
Area of Science:
- Obstetrics and Gynecology
- Pharmacology
- Maternal-Fetal Medicine
Background:
- Pre-eclampsia is linked to an imbalance in prostacyclin and thromboxane production.
- This imbalance suggests that antiplatelet agents may prevent or delay pre-eclampsia.
Purpose of the Study:
- To evaluate the effectiveness and safety of antiplatelet agents for preventing pre-eclampsia in at-risk pregnant women.
Main Methods:
- A systematic review and meta-analysis of 51 randomized controlled trials involving 36,500 women.
- Searched multiple databases including Cochrane Pregnancy and Childbirth Group trials register, Cochrane Central Register of Controlled Trials, and EMBASE.
Main Results:
- Antiplatelet agents reduced the risk of pre-eclampsia by 19% (NNT 69).
- A 16% reduction in fetal or neonatal deaths was observed (NNT 227).
- Small reductions in preterm birth (7%) and small-for-gestational age babies (8%) were also noted.
Conclusions:
- Antiplatelet agents, primarily low-dose aspirin, offer moderate benefits in preventing pre-eclampsia.
- More research is needed to identify optimal patient selection, treatment timing, and dosage.